Antifungals: What's in the pipeline

Current Opinion in Microbiology

Volumn 4, Issue 5, 2001, Pages 540-545

  Tkacz, Jan S ^a   DiDomenico, Beth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; FR 901379; ITRACONAZOLE; MICAFUNGIN; PNEUMOCANDIN DERIVATIVE; POSACONAZOLE; PROTEIN INHIBITOR; PYRROLE DERIVATIVE; RAVUCONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE; WF 11899A;

ACYLATION; ASPERGILLUS; CANDIDA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; HUMAN; REVIEW;

EID: 0034787663     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(00)00248-4     Document Type: Review

References (53)

1. Introduction to antifungal drugs
2. Anti-Candida drugs - The biochemical basis for their activity
3. Cytochrome P450-dependent 14 alpha-sterol demethylase of Candida albicans and its interaction with azole antifungals
4. Antifungals: Mechanism of action and resistance, established and novel drugs
5. Molecular aspects of azole antifungal action and resistance
6. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa
7. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
8. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B
9. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans
10. Current and emerging azole antifungal agents
11. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
12. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis
13. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice
14. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
15. Treatment of murine fusariosis with SCH 56592
16. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ('Ramichloridium mackenzief)
17. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi
18. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp.
19. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens
20. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592)
21. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole
22. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida
23. In vitro susceptibilities of Candida blood stream isolates to the new triazole antifungal agents BMS-207147, Sch56592, and voriconazole
24. Antifungal drug resistance in pathogenic fungi
25. Voriconazole against fluconazole-susceptible and resistant Candida isolates: In vitro efficacy compared with that of itraconazole and ketoconazole
26. In vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp.
27. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection?
28. FK463, a novel water-soluble echinocandin lipopeptide: Synthesis and antifungal activity
29. o derivatives
30. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
31. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): Structure-activity studies of the lipophilic and geometric parameters of polyarylated acyl analogs of ECB
32. Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs
33. Lipopeptide inhibitors of fungal glucan synthase
34. Cell wall maintenance in fungi
35. Glucan synthase complex of Aspergillus fumigatus
36. Photoaffinity analog of the semisynthetic echinocandin LY303366: Identification of echinocandin targets in Candida albicans
37. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi
38. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus furnigatus in a murine model of invasive aspergillosis
39. Efficacy of FK463, a (1,3)-β-D-glucan synthase inhibitor, in disseminated azole-resistant Candida albicans infection in mice
40. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
41. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model
42. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds
43. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
44. Antifungal efficacy, safety, and single dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits
45. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits
46. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine
47. Caspofungin, FK463, LY 303366
48. Progress in antifungal chemotherapy
49. Genetic modifications of an echinocandin B-producing strain of Aspergillus nidulans to produce mutants blocked in sterigmatocystin biosynthesis
50. Reclassification of a pneumocandin-producing anamorph, Glarea lozoyensis gen. et sp. nov., previously identified as Zalerion arboricola
51. Biosynthesis of L-671,329, an echinocandin type antibiotic produced by Zalerion arboricola: Origins of some of the unusual amino acids and the dimethylmyristic acid side-chain
52. o